Study Objectives: To determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana.

Study Design: Randomized clinical trial

Study Population: Pregnant women living with HIV and their infants

Study Duration: 24 months

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Study Findings

All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%.